Advertisement

The Pathogenetic Significance of Deregulated Transcription Factors in Hematological Malignancies

  • Masahiro Nakagawa
  • Susumu Goyama
  • Motoshi Ichikawa
  • Mineo Kurokawa
Conference paper

Hematological malignancies have been treated with traditional chemotherapy, such as alkylating agents, anthracycline, or antimetabolites. These conventional chemotherapies are not specific to malignant cells, and severe side effects are unavoidable with intensive chemotherapy. Therefore, it might be difficult to improve the cure rate further with conventional chemotherapy. Hematopoietic stem cell transplantation (HSCT) is a powerful and curable treatment, but it is very invasive. Patients sometimes suffer from severe side effects, such as graft-versus-host disease (GVHD), and HSCT may also cause premature death. In addition, it is sometimes difficult to find appropriate donors. In recent years, with the great advances in molecular biology, genetics, biochemistry, and systems biology, we gradually come to understand the molecular mechanisms of pathogenesis in hematological malignancies. Molecular targeted therapy targets molecules or pathways that play critical roles in maintaining hematological malignancies. In contrast to conventional chemotherapy, molecular targeted therapy is highly specific to malignant cells and has minimal side effects. Currently, the most successful molecular targeted therapy is imatinib, a relatively specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia (CML). Imatinib dramatically changed the standard therapy and indication of HSCT for CML [1,2]. However, in contrast to CML, which is relatively homogeneous, molecular pathogenesis and therapeutic targets are largely unknown in many hematological malignancies. Therefore, we definitely need to elucidate molecular mechanisms of pathogenesis in other types of hematopoietic malignancies. Classically, we analyzed the functions of molecules individually, which method was not necessarily efficient. To extensively clarify molecular pathogenesis in many hematological malignancies, we applied bioinfor-matics and systems biology. We made genome-wide analyses of intracellular changes caused by leukemia-associated transcriptional factors, with the intention to comprehend total molecular pathogenesis and to identify therapeutic targets.

Keywords

Acute Myeloid Leukemia Chronic Myeloid Leukemia Hematopoietic Stem Cell Transplantation Hematological Malignancy Acute Myeloid Leukemia Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Druker BJ et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 35523:2408–2417CrossRefGoogle Scholar
  2. 2.
    Hehlmann R et al (2007) Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 10911:4686–4692CrossRefGoogle Scholar
  3. 3.
    Iwasaki H, Akashi K (2007) Hematopoietic developmental pathways: on cellular basis. Oncogene 2647:6687–6696CrossRefGoogle Scholar
  4. 4.
    Lutterbach B, Hiebert SW (2000) Role of the transcription factor AML-1 in acute leukemia and hematopoietic differentiation. Gene (Amst) 2452:223–235Google Scholar
  5. 5.
    Okuda T et al (1996) AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 842:321–330CrossRefGoogle Scholar
  6. 6.
    Wang Q et al (1996) Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci USA 938:3444–3449CrossRefGoogle Scholar
  7. 7.
    Ichikawa M et al (2004) AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med 103:299–304CrossRefGoogle Scholar
  8. 8.
    Ichikawa M et al (2008) AML1/Runx1 negatively regulates quiescent hematopoietic stem cells in adult hematopoiesis. J Immunol 1807:4402–4408Google Scholar
  9. 9.
    Mucenski ML et al (1988) Identification of a common ecotropic viral integration site, Evi-1, in the DNA of AKXD murine myeloid tumors. Mol Cell Biol 81:301–308Google Scholar
  10. 10.
    Ogawa S et al (1996) Abnormal expression of Evi-1 gene in human leukemias. Hum Cell 94:323–332Google Scholar
  11. 11.
    Suzukawa K et al (1994) Identification of a breakpoint cluster region 3 of the ribophorin I gene at 3q21 associated with the transcriptional activation of the EVI1 gene in acute myelog-enous leukemias with inv(3)(q21q26). Blood 848:2681–2688Google Scholar
  12. 12.
    Pintado T et al (1985) Clinical correlations of the 3q21;q26 cytogenetic anomaly. A leukemic or myelodysplastic syndrome with preserved or increased platelet production and lack of response to cytotoxic drug therapy. Cancer (Phila) 553:535–541Google Scholar
  13. 13.
    Barjesteh van Waalwijk van Doorn-Khosrovani S et al (2003) High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 1013:837–845CrossRefGoogle Scholar
  14. 14.
    Valk PJ et al (2004) Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 35016:1617–1628CrossRefGoogle Scholar
  15. 15.
    Kurokawa M et al (1998) The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3. Nature (Lond) 3946688:92–96Google Scholar
  16. 16.
    Kurokawa M et al (2000) The evi-1 oncoprotein inhibits c-Jun N-terminal kinase and prevents stress-induced cell death. EMBO J 1912:2958–2968CrossRefGoogle Scholar
  17. 17.
    Tanaka T et al (1994) Evi-1 raises AP-1 activity and stimulates c-fos promoter transactivation with dependence on the second zinc finger domain. J Biol Chem 26939:24020–24026Google Scholar
  18. 18.
    Morishita K et al (1992) Expression of the Evi-1 zinc finger gene in 32Dc13 myeloid cells blocks granulocytic differentiation in response to granulocyte colony-stimulating factor. Mol Cell Biol 121:183–189Google Scholar
  19. 19.
    Goyama S et al (in press) Cell Stem CellGoogle Scholar
  20. 20.
    Mootha VK et al (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 343:267–273CrossRefGoogle Scholar
  21. 21.
    Subramanian A et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 10243: 15545–15550CrossRefGoogle Scholar
  22. 22.
    Yuasa H et al (2005) Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression. EMBO J 2411:1976–1987CrossRefGoogle Scholar

Copyright information

© Springer 2009

Authors and Affiliations

  • Masahiro Nakagawa
    • 1
  • Susumu Goyama
    • 1
  • Motoshi Ichikawa
    • 1
  • Mineo Kurokawa
    • 1
  1. 1.Department of Hematology and Oncology, Graduate School of Medicine, University of TokyoThe University of Tokyo HospitalBunkyo-kuJapan

Personalised recommendations